Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
about
Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysisWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis.The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.Development and validation of a risk score for serious infection in patients with rheumatoid arthritis.RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic ArthritisHow predictive of dementia are peripheral inflammatory markers in the elderly?Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisHarms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures.Multifocal infections of the musculoskeletal system: description of a safe one-step procedure for eradication of associated spinal infections.Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.Tumour necrosis factor in infectious disease.Clinical management of septic arthritis.Biological therapies for psoriasis.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Long-term safety of immunomodulators in pediatric inflammatory diseases.Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.Cytomegalovirus, inflammatory bowel disease, and anti-TNFα.[Juvenile rheumatoid diseases: Endoprosthetic care of destroyed hip joints].Prognostic factors associated with mortality in patients with septic arthritis: a descriptive cohort study.RABBIT risk score and ICU admission due to infection in patients with rheumatoid arthritis.Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report.Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty.A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013.[Infections of non-prosthetically treated joints].The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.Septic arthritis in gout patients: a population-based cohort study.Monoarthritis in a 28-Year-Old Man With Juvenile Idiopathic Arthritis.Predictors of treatment failure and mortality in native septic arthritis.Rheumatoid arthritis patients with hip fracture: a nationwide study.Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis.
P2860
Q26786213-F477633E-245E-4094-B8C9-739D4A546AF3Q28074148-6FFF541B-84CC-4451-B1A8-2594F4067A5DQ30574065-7D000D6A-04DE-455B-84DA-5A917277F6F3Q31152756-F19A9F82-1F08-4D0D-B18B-4A1EA0012B08Q33869944-F6CCAA41-158F-4480-99E8-959DB763CDF9Q35200354-8D4EDBFC-CCE7-4787-9E54-1E1C4602CD10Q35559234-C7797FDE-5204-40FE-AEC1-CE2AA23354C6Q35838797-D182D27E-E96A-4148-8A11-E2343FAB724FQ36179586-D6796310-5335-4625-A9E4-22C986B8180FQ36209840-1EE04E3B-ECF8-45E8-A410-9E8EB90C16C8Q36630566-05AAFFC0-3B59-424E-8C29-CA5521234293Q36968737-1831A27D-4186-4D63-9ACD-8C7EDADE3BCFQ37189376-7B9DF7ED-5C34-482C-980F-762EA2DC6F6AQ37292803-E435650D-4DBD-4995-9D3C-7319574F813FQ37361961-8186715F-1C08-4285-B303-912D9852BFE5Q37599165-722F2B06-61E0-4F6F-A01B-ADB9D7C6A5C4Q38063474-6619592A-91AF-4A77-8405-2C34FDCB489FQ38086506-B4A1D7A8-5BEC-4648-A049-580DCA19575DQ38099554-5B525756-E71C-43C5-8C61-B13B07CEA5ECQ38155648-34435B00-6197-4FEF-B154-47AE1F2C7702Q38176745-3D0C6F59-C470-40EF-BE97-A85587C4D136Q38192553-320DF97E-60A7-40A8-9288-1A7220E2CA71Q38232338-5EA0F34B-6009-4235-A602-AE56567D96EDQ38445319-9AAA1EFC-8C1A-4C7F-95F9-6BB79DA1A963Q38458992-124EE168-A45F-4D48-8725-97CD4B0AE0A0Q38668352-64C3F6D4-28C6-423A-98C8-7A8884E6E013Q39022584-5A8DB52A-012A-49FE-A98F-845C54E8E38FQ39189780-39BD81EE-6EC2-4615-973B-0DB72116DBA7Q39679185-3413D79F-7137-4670-9766-B2E626909B1BQ40047290-201944C0-4A07-4D94-B3CD-9F3E0969EE3EQ40293678-E101846C-1C25-4A64-828E-19B1F6E3CAEDQ40355795-3752B046-19B5-4D90-8BD2-3B6B57FE9FBBQ40537125-B04C44DD-AF66-4A1A-99DA-D0400D6BE987Q40557887-10B54AB4-8B75-4CDD-BE6B-0DA9AF4235F8Q40676691-B14A48B2-E18A-4025-9EA6-D5444D1690DFQ40742033-70D7D222-4AA2-497D-AACE-62BE865D2D59Q41363297-E9726D50-EC26-433B-90D0-1C8B18D0F276Q41602245-8DEE9971-6F2B-48FA-BF7C-B82D3BD7044BQ41655752-D9F88DC2-EB21-4BC5-B503-C1C9B21FA60AQ42030573-EE03D83F-7AA0-4C1D-B181-2D0FE2CDACFC
P2860
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@ast
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@en
type
label
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@ast
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@en
prefLabel
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@ast
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@en
P2093
P2860
P356
P1476
Risk of septic arthritis in pa ...... eumatology Biologics Register.
@en
P2093
A P Ustianowski
BSR Biologics Register
D P M Symmons
J B Galloway
K D Watson
K L Hyrich
L K Mercer
P2860
P304
P356
10.1136/ARD.2011.152769
P407
P50
P577
2011-07-21T00:00:00Z